Premium
Platelet factor 4 mRNA expression in cells from a patient with megakaryoblastic crisis of chronic myelogenous leukemia
Author(s) -
Ryo Ryukichi,
Adachi Masashi,
Sugano Wataru,
Yasunaga Mutsumi,
Yoshida Akinori,
Jikai Jiang,
Saigo Katsuyasu,
Yamaguchi Nobuo,
Akita Hozuka,
Yokoyama Mitsuhiro,
Konaka Yoshiteru,
Poncz Mortimer
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910215)67:4<960::aid-cncr2820670418>3.0.co;2-v
Subject(s) - medicine , chronic myelogenous leukemia , blast crisis , messenger rna , leukemia , acute megakaryoblastic leukemia , cancer research , platelet , immunology , gene , genetics , biology
A 61‐year‐old man with Philadelphia chromosome‐positive chronic myelogenous leukemia developed megakaryoblastic leukemia. In the blast phase, his blast cells showed undifferentiated megakaryoblastic characteristics with no α‐granules or demarcation membranes but with detectable platelet peroxidase (PPO) activity and surface glycoprotein (GP) IIb/IIIa. The patient has remained reasonably well for at least 12 months after blastic crisis, and 6‐mercaptopurine alone has been effective in controlling leukocytosis and megakaryoblast proliferation. The expression of mRNA for platelet‐specific proteins, such as GPIIb and platelet factor 4 (PF4), was studied in the patient's blast cells by the Northern blot analysis. Both GPIIb and PF4 mRNA were detected in the blast cells. Cytoplasmic maturation occurs later than the synthesis of the surface GP during megakaryocyte maturation. Therefore, PF4 mRNA expression should be a marker of mature megakaryoblasts. The PF4 mRNA expression in megakaryoblastic leukemia may indicate that a patient will have long survival and a good response to chemotherapy.